PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (SEXUAL HEALTH)
DRUG NAME: PT-141 (BREMELANOTIDE)

• FDA Safety Data Sheet may be found here.

• Mayer D. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 [PubMed Link]

• Dhillon S. Bremelanotide: First Approval. Drugs. 2019 [PubMed Link]

• Edinoff AN. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022 [PubMed Link]

• Pfaus JG. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022 [PubMed Link]

• Cipriani S. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opin Pharmacother. 2023 [PubMed Link]

• Nappi RE. Medical Treatment of Female Sexual Dysfunction. Urol Clin North Am. 2022 [PubMed Link]

• Kingsberg SA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 [PubMed Link]

• Pettigrew JA, Novick AM. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. J Midwifery Womens Health. 2021 [PubMed Link]